Citation
Chan, Kwok-Hung, et al. "Cross-reactive Antibodies in Convalescent SARS Patients' Sera Against the Emerging Novel Human Coronavirus EMC (2012) By Both Immunofluorescent and Neutralizing Antibody Tests." The Journal of Infection, vol. 67, no. 2, 2013, pp. 130-40.
Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect. 2013;67(2):130-40.
Chan, K. H., Chan, J. F., Tse, H., Chen, H., Lau, C. C., Cai, J. P., Tsang, A. K., Xiao, X., To, K. K., Lau, S. K., Woo, P. C., Zheng, B. J., Wang, M., & Yuen, K. Y. (2013). Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. The Journal of Infection, 67(2), 130-40. https://doi.org/10.1016/j.jinf.2013.03.015
Chan KH, et al. Cross-reactive Antibodies in Convalescent SARS Patients' Sera Against the Emerging Novel Human Coronavirus EMC (2012) By Both Immunofluorescent and Neutralizing Antibody Tests. J Infect. 2013;67(2):130-40. PubMed PMID: 23583636.
TY - JOUR
T1 - Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests.
AU - Chan,Kwok-Hung,
AU - Chan,Jasper Fuk-Woo,
AU - Tse,Herman,
AU - Chen,Honglin,
AU - Lau,Candy Choi-Yi,
AU - Cai,Jian-Piao,
AU - Tsang,Alan Ka-Lun,
AU - Xiao,Xincai,
AU - To,Kelvin Kai-Wang,
AU - Lau,Susanna Kar-Pui,
AU - Woo,Patrick Chiu-Yat,
AU - Zheng,Bo-Jiang,
AU - Wang,Ming,
AU - Yuen,Kwok-Yung,
Y1 - 2013/04/10/
PY - 2013/01/28/received
PY - 2013/03/27/revised
PY - 2013/03/31/accepted
PY - 2013/4/16/entrez
PY - 2013/4/16/pubmed
PY - 2014/1/18/medline
SP - 130
EP - 40
JF - The Journal of infection
JO - J Infect
VL - 67
IS - 2
N2 - OBJECTIVES: A severe acute respiratory syndrome (SARS)-like disease due to a novel betacoronavirus, human coronavirus EMC (HCoV-EMC), has emerged recently. HCoV-EMC is phylogenetically closely related to Tylonycteris-bat-coronavirus-HKU4 and Pipistrellus-bat-coronavirus-HKU5 in Hong Kong. We conducted a seroprevalence study on archived sera from 94 game-food animal handlers at a wild life market, 28 SARS patients, and 152 healthy blood donors in Southern China to assess the zoonotic potential and evidence for intrusion of HCoV-EMC and related viruses into humans. METHODS: Anti-HCoV-EMC and anti-SARS-CoV antibodies were detected using screening indirect immunofluorescence (IF) and confirmatory neutralizing antibody tests. RESULTS: Two (2.1%) animal handlers had IF antibody titer of ≥ 1:20 against both HCoV-EMC and SARS-CoV with neutralizing antibody titer of <1:10. No blood donor had antibody against either virus. Surprisingly, 17/28 (60.7%) of SARS patients had significant IF antibody titers with 7/28 (25%) having anti-HCoV-EMC neutralizing antibodies at low titers which significantly correlated with that of HCoV-OC43. Bioinformatics analysis demonstrated a significant B-cell epitope overlapping the heptad repeat-2 region of Spike protein. Virulence of SARS-CoV over other betacoronaviruses may boost cross-reactive neutralizing antibodies against other betacoronaviruses. CONCLUSIONS: Convalescent SARS sera may contain cross-reactive antibodies against other betacoronaviruses and confound seroprevalence study for HCoV-EMC.
SN - 1532-2742
UR - https://www.unboundmedicine.com/medline/citation/23583636/Cross_reactive_antibodies_in_convalescent_SARS_patients'_sera_against_the_emerging_novel_human_coronavirus_EMC__2012__by_both_immunofluorescent_and_neutralizing_antibody_tests_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-4453(13)00071-6
DB - PRIME
DP - Unbound Medicine
ER -
